APC is an inclusion eligibility criterion in 7 clinical trials for medulloblastoma, of which 7 are open and 0 are closed. Of the trials that contain APC status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].

ATM is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK6 is an inclusion eligibility criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain CDK6 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [3].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 5 clinical trials for medulloblastoma, of which 5 are open and 0 are closed. Of the trials that contain CTDNEP1 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [3].

CTNNA1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNA1 status and medulloblastoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CTNNA2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNA2 status and medulloblastoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CTNNA3 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNA3 status and medulloblastoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [3].

CTNNB1 is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain CTNNB1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].

DDX3X is an inclusion eligibility criterion in 10 clinical trials for medulloblastoma, of which 10 are open and 0 are closed. Of the trials that contain DDX3X status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].

EGFR is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for medulloblastoma, of which 0 are open and 2 are closed. Of the trials that contain ERBB2 status and medulloblastoma as inclusion criteria, 2 are phase 1/phase 2 (0 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB4 status and medulloblastoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GLI2 is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain GLI2 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 3 clinical trials for medulloblastoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

HGF is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A is an inclusion eligibility criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain KDM6A status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [3].

KMT2C is an inclusion eligibility criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain KMT2C status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [3].

KMT2D is an inclusion eligibility criterion in 10 clinical trials for medulloblastoma, of which 10 are open and 0 are closed. Of the trials that contain KMT2D status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].

LRP1B is an inclusion eligibility criterion in 5 clinical trials for medulloblastoma, of which 5 are open and 0 are closed. Of the trials that contain LRP1B status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain MDM4 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

MET is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is an inclusion eligibility criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain MYC status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [3].

MYCL is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain MYCL status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

MYCN is an inclusion eligibility criterion in 12 clinical trials for medulloblastoma, of which 12 are open and 0 are closed. Of the trials that contain MYCN status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

OTX2 is an inclusion eligibility criterion in 5 clinical trials for medulloblastoma, of which 5 are open and 0 are closed. Of the trials that contain OTX2 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain PPM1D status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

PTCH1 is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain PTCH1 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

PTEN is an inclusion eligibility criterion in 9 clinical trials for medulloblastoma, of which 9 are open and 0 are closed. Of the trials that contain PTEN status and medulloblastoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 5 clinical trials for medulloblastoma, of which 5 are open and 0 are closed. Of the trials that contain PVT1 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RELA is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RELA status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain SHH status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is an inclusion eligibility criterion in 9 clinical trials for medulloblastoma, of which 9 are open and 0 are closed. Of the trials that contain SMARCA4 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].

SMO is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain SMO status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

SNCAIP is an inclusion eligibility criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain SNCAIP status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [3].

SUFU is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain SUFU status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

TERT is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain TERT status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

TP53 is an inclusion eligibility criterion in 10 clinical trials for medulloblastoma, of which 10 are open and 0 are closed. Of the trials that contain TP53 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 4 are phase 2 (4 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open) [3].

YAP1 is an inclusion eligibility criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain YAP1 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [3].

ZMYM3 is an inclusion eligibility criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain ZMYM3 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [3].